David Hoang
Stock Analyst at Deutsche Bank
(4.07)
# 868
Out of 5,182 analysts
50
Total ratings
55%
Success rate
13.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintains: Buy | $55 → $88 | $71.90 | +22.39% | 2 | Apr 14, 2026 | |
| ATAI AtaiBeckley | Initiates: Buy | $12 | $4.34 | +176.50% | 1 | Mar 27, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $56 → $90 | $54.26 | +65.87% | 4 | Mar 10, 2026 | |
| APGE Apogee Therapeutics | Initiates: Buy | $103 | $86.49 | +19.09% | 1 | Dec 10, 2025 | |
| ALKS Alkermes | Maintains: Buy | $55 → $45 | $33.73 | +33.41% | 3 | Nov 13, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $65 → $280 | $330.99 | -15.41% | 2 | Oct 17, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $54 → $36 | $31.05 | +15.94% | 4 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Sell | $6 → $12 | $20.98 | -42.80% | 10 | Aug 15, 2025 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $20 → $35 | $22.30 | +56.95% | 5 | May 21, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $19.94 | +55.47% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $9.59 | +577.79% | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $176 | $187.40 | -6.08% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $128.04 | +23.40% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $2.52 | +177.78% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $7.50 | +113.33% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $3.76 | +325.53% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $308.51 | -28.69% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $73.60 | +8.70% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $0.35 | +760.83% | 1 | Dec 7, 2022 |
Spyre Therapeutics
Apr 14, 2026
Maintains: Buy
Price Target: $55 → $88
Current: $71.90
Upside: +22.39%
AtaiBeckley
Mar 27, 2026
Initiates: Buy
Price Target: $12
Current: $4.34
Upside: +176.50%
Xenon Pharmaceuticals
Mar 10, 2026
Maintains: Buy
Price Target: $56 → $90
Current: $54.26
Upside: +65.87%
Apogee Therapeutics
Dec 10, 2025
Initiates: Buy
Price Target: $103
Current: $86.49
Upside: +19.09%
Alkermes
Nov 13, 2025
Maintains: Buy
Price Target: $55 → $45
Current: $33.73
Upside: +33.41%
Praxis Precision Medicines
Oct 17, 2025
Maintains: Buy
Price Target: $65 → $280
Current: $330.99
Upside: -15.41%
Harmony Biosciences Holdings
Sep 25, 2025
Maintains: Buy
Price Target: $54 → $36
Current: $31.05
Upside: +15.94%
Sarepta Therapeutics
Aug 15, 2025
Maintains: Sell
Price Target: $6 → $12
Current: $20.98
Upside: -42.80%
ACADIA Pharmaceuticals
May 21, 2025
Upgrades: Buy
Price Target: $20 → $35
Current: $22.30
Upside: +56.95%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $19.94
Upside: +55.47%
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $9.59
Upside: +577.79%
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $187.40
Upside: -6.08%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $128.04
Upside: +23.40%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $2.52
Upside: +177.78%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $7.50
Upside: +113.33%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $3.76
Upside: +325.53%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $308.51
Upside: -28.69%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $73.60
Upside: +8.70%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $0.35
Upside: +760.83%